Impact of Metformin Use on Clinical and Pathological Outcomes in Breast Cancer Patients With Type 2 Diabetes
Abstract
BACKGROUND: Breast cancer is the most common malignancy in women, and its incidence is increasing worldwide. Type 2 diabetes mellitus (T2DM) is a significant comorbidity in patients with breast cancer that negatively affects prognosis. Metformin, a first-line antidiabetic drug, has been suggested to possess antineoplastic properties. This study investigated the effects of metformin on the demographic characteristics, pathological parameters, treatment response, and prognosis of breast cancer patients with T2DM in an Iranian population.
METHODS: A retrospective cross-sectional study was conducted on 104 patients with breast cancer and T2DM at the Velayat Educational and Therapeutic Center, Qazvin, Iran, from 2019 to 2023. The patients were categorized into two groups: metformin users (n = 46) and non-users (n = 58). Data on demographic characteristics, disease stage, lymph node involvement, hormone receptor status, treatment response, prognosis, recurrence, and metastasis were collected. Statistical analyses were performed using SPSS version 25, with significance set at p < 0.05. Unadjusted and adjusted logistic regression analyses were performed to identify independent predictors of prognosis.
RESULTS: The mean disease duration was significantly shorter in the metformin group than in the non-metformin group (p = 0.036). A significant difference was observed in the stage of disease (p = 0.003), with metformin users more frequently presenting at earlier stages. Lymph node…
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 104 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.